Related Experiment Video
Updated: Jul 8, 2026
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
Different immune correlates associated with tumor progression and regression: implications for prevention and
Duane H Hamilton1, Peter A Bretscher
1Department of Microbiology and Immunology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada, S7N 5E5.
Abstract:
Observations show that humans and animals respond immunologically to most cancers. Why does the immune system then fail to control cancer? We argue from the literature that there is a commonality in the regulation of responses against most murine tumors, and that a major mechanism of escape may be deviation of an effective Th1, cytotoxic T lymphocyte response to a less effective response with a Th2 component. We examined this hypothesis with two well-studied murine tumors. We found, following primary tumor implantation, that resistance correlates with Th1 responses and IgG2a antibody production and progression with mixed Th1/Th2 responses and production of IgG1 and IgG2a antibodies. Resistance is associated with a modulation of the anti-tumor response towards the Th1 pole in both systems. We conclude that the immune responses against these two tumors are in accord with our hypothesis, and argue that this is likely to be true of many human and murine tumors. The correlation of IgG isotype of anti-tumor antibody with the Th1/Th2 nature of the anti-tumor response readily allows one to longitudinally monitor the changing nature of the anti-tumor response. We suggest that such monitoring can guide immunotherapy to maximize the effectiveness of the host's immune response against cancer.
Insights
The immune system often fails to control cancer due to a shift from effective Th1 responses to less effective Th2 responses. Monitoring antibody isotypes can guide immunotherapy for better cancer treatment.
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- The immune system can recognize and respond to cancer, yet it frequently fails to eliminate tumors.
- Tumor cells may evade immune detection through regulatory mechanisms that suppress effective anti-cancer responses.
Purpose of the Study:
- To investigate the hypothesis that a shift from T-helper 1 (Th1) to T-helper 2 (Th2) immune responses contributes to cancer progression.
- To examine the correlation between specific immune responses and tumor outcomes in murine models.
Main Methods:
- Analysis of immune responses, including T-helper cell profiles (Th1/Th2) and antibody isotypes (IgG1, IgG2a), in mice bearing tumors.
- Longitudinal monitoring of anti-tumor immune responses during tumor progression and resistance.
Main Results:
- Tumor resistance was associated with dominant Th1 responses and specific antibody production (IgG2a).
- Tumor progression correlated with mixed Th1/Th2 responses and production of both IgG1 and IgG2a antibodies.
- Immune responses were modulated towards a Th1-dominant profile in resistant tumor systems.
Conclusions:
- The findings support the hypothesis that a deviation towards Th2 responses facilitates tumor immune evasion.
- Monitoring anti-tumor antibody isotypes (e.g., IgG subclasses) can serve as a biomarker for the type of immune response.
- This monitoring approach may guide the development of more effective cancer immunotherapies.
Related Concept Videos
01:27Tumor Immunotherapy
02:17The Tumor Microenvironment
02:17The Tumor Microenvironment
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...